Skip to content

Efficacy and Safety of Morning OR Evening Antihypertensive Drugs Administration on Albuminuria in Hypertensive Patients (MORE trial): An Open-Label, Assessor-Masked, Pilot Randomized Controlled Trial

Efficacy and Safety of Morning or Evening Antihypertensive Drugs Administration on Albuminuria in Hypertensive Patients (MORE trial): An Open-Label, Assessor-Masked, Pilot Randomized Controlled Trial

Status
Active, not recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
TCTR
Registry ID
TCTR20240930002
Enrollment
60
Registered
2024-09-30
Start date
2021-03-08
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients with hypertension presenting albuminuria more than 30 mg/g and taking more than one antihypertensive class more than 3 months albuminuria, albumin creatinine ratio, evening, hypertension, morning

Interventions

taking antihypertensive pills in the morning at 6.00 to 10.00 am ,taking antihypertensive pills in the evening at 18.00 to 22.00 pm
Active Comparator Drug,Active Comparator Drug
Morning group,Evening antihypertensive drugs

Sponsors

Navamindradhiraj University, Thailand
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. age 18-80 years 2. diagnosis of hypertension more than 1 year 3. At least one antihypertensive agent for more than 3 months 4. At least one antihypertensive agent in Angiotensin-converting enzyme inhibitor (ACEI) and/or Angiotensin receptor blocker (ARB) 5. Well controlled blood pressure (systolic blood pressure < 150 mmHg, Diastolic blood pressure < 90 mmHg) 6.albuminuria > 30 mg/g 7.Renal function (estimated glomerular filtration rate, eGFR > 15 ml/min/1.73 m2)

Exclusion criteria

Exclusion criteria: End stage kidney disease Poor control blood pressure Severe comorbid disease for example congestive heart failure, active cancer Pregnancy Inflammatory disease or active infection for example arthritis, pyelonephritis

Design outcomes

Primary

MeasureTime frame
Log urine albumin creatinine ratio 3 months after intervention log UACR, mg/g

Secondary

MeasureTime frame
kidney function 3 months after intervention eGFR, mL/min/1.73 m2, Decreased in eGFR of 15% or more from baseline,Effects of blood pressure 3 months after intervention Blood pressure control ,Decreased in UACR 3 months after intervention Decreased in UACR of 30% or more from baseline

Countries

Thailand

Contacts

Public ContactThanpisit Trakarnvanich

Faculty of Medicine, Navamindradhiraj University

thanphisit@nmu.ac.th0896996830

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026